Vykat XR (diazoxide choline-extended release): a new FDA-approved treatment for hyperphagia in Prader–Willi syndrome
On March 27, 2025, the U.S. Food and Drug Administration (FDA) approved Vykat XR (diazoxide choline-extended release tablets) for the treatment of hyperphagia in individuals aged 4 years and older with Prader-Willi Syndrome (PWS). This marks the first FDA-approved pharmacologic therapy targeting hyperphagia in this population, addressing a long-standing unmet need and offering new hope for patients, caregivers, and clinicians.
Authors
- Prakriti Pokhrel (ORCID: https://orcid.org/0000-0002-9455-2249)
- Gerardo F Ferrer
- Laraib Fatima
- Amrah Abdul Samad
- Hidhaya S. Noorul
Institutions
- Stanley Medical College (IN)
- Larkin Community Hospital (US)
- Dow University of Health Sciences (PK)
- Bahria University (PK)
- Kathmandu Medical College Teaching Hospital (NP)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2026-04-03
- DOI
- https://doi.org/10.1097/ms9.0000000000004938
- Primary Topic
- Genetic Syndromes and Imprinting
- Type
- article
- Field-Weighted Citation Impact
- 0.00